Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 19-28z/IL-18 CAR-T cells |
| Synonyms | |
| Therapy Description |
19-28z/IL-18 CAR-T cells are T-lymphocytes engineered to express IL-18 and a chimeric antigen receptor (CAR) targeting CD19, which may lead to enhanced antitumor immune response and inhibition of tumor growth (PMID: 29768210). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 19-28z/IL-18 CAR-T cells | CD19 Immune Cell Therapy 72 | 19-28z/IL-18 CAR-T cells are T-lymphocytes engineered to express IL-18 and a chimeric antigen receptor (CAR) targeting CD19, which may lead to enhanced antitumor immune response and inhibition of tumor growth (PMID: 29768210). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06287528 | Phase I | 19-28z/IL-18 CAR-T cells | A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) | Recruiting | USA | 0 |